GLP-1 receptor agonists reduce kidney failure risk and cardiovascular events Post author: Post published:November 27, 2024 Post category:uncategorized Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes. You Might Also Like For people with sickle cell disease, ERs can mean life-threatening waits October 17, 2023 Abnormal BMI in children linked to impaired lung function October 28, 2024 New discovery shows piRNA’s adaptive role in silencing jumping genes March 20, 2025